IVI RMA North America Presents Pioneering Reproductive Medicine Studies at ASRM 2025
IVI RMA North America, a leading provider of fertility care and assisted reproductive technologies, is set to make a significant impact at the upcoming American Society for Reproductive Medicine (ASRM) Annual Scientific Congress & Expo, taking place in San Antonio, Texas, from October 25-29, 2025. The ASRM Annual Congress is widely recognized as the premier global gathering for professionals in reproductive medicine, encompassing specialties such as infertility, contraception, menopause, and embryology. The event serves as a vital platform for showcasing cutting-edge research, technological innovations, and clinical advancements in reproductive health, providing attendees with the opportunity to engage with pioneering work from around the world.
At this year’s congress, IVI RMA North America will deliver an impressive 36 presentations and poster sessions, highlighting the organization’s leadership in reproductive medicine research and patient care. More than 100 IVI RMA North America reproductive endocrinologists, clinicians, scientists, and researchers will present studies that address a wide array of clinically relevant questions. Their work spans critical topics such as nutrition and reproductive health, cryopreservation techniques, sperm testing and motility, ovarian stimulation protocols, the viability of embryos with chromosomal abnormalities, polycystic ovary syndrome (PCOS), recurrent pregnancy loss, and the seasonality of pregnancy outcomes.
Beyond North America, IVI RMA researchers from across five countries have had their studies selected for presentation at ASRM 2025. These international contributions include high-impact research exploring fertility in unique populations and the use of artificial intelligence (AI) in oocyte and embryo assessment. This global participation underscores IVI RMA’s commitment to advancing reproductive science through rigorous, collaborative research, highlighting the organization’s influence on the international stage.
Building on its momentum in North America, IVI RMA Global continues to lead innovation in reproductive medicine. Across the U.S. and worldwide, IVI RMA researchers will contribute an impressive 65 scientific posters and presentations at ASRM 2025, reflecting the depth and breadth of the organization’s research capabilities. These contributions demonstrate IVI RMA’s ongoing dedication to developing evidence-based solutions that advance reproductive health and improve patient outcomes on a global scale.
Dr. Thomas Molinaro, Chief Medical Officer of IVI RMA North America, emphasized the organization’s commitment to scientific excellence and innovation: “IVI RMA continues to invest time, technology, talent, and funding into studying the most important reproductive medicine questions. Our goal is to generate incremental improvements and breakthroughs that push the industry forward, raise the standards of care, and ultimately help patients build families. Our ASRM 2025 research will provide a comprehensive exploration of family building and highlight the innovations shaping the future of reproductive medicine.”
The research presented by IVI RMA at ASRM 2025 covers a wide range of topics that are shaping clinical practice and patient care. Among these, several key areas stand out:
1. Access and Affordability in Reproductive Medicine
IVI RMA research is examining how policy improvements, financial support, and patient education can expand access to reproductive care. With more young women opting to freeze their eggs for future family planning, understanding barriers to affordability and accessibility has become increasingly important. Studies presented at ASRM 2025 will highlight strategies to make reproductive medicine more inclusive, ensuring that more individuals can benefit from advanced fertility technologies.
2. Advancements in Male Infertility Testing
Although male factors contribute to nearly half of all infertility cases, many abnormalities go undetected using conventional testing methods. IVI RMA researchers have explored novel sperm tests capable of more accurately identifying underlying problems, providing crucial insights that can inform treatment strategies and improve outcomes for couples experiencing infertility.
3. Consistency in Pre-Implantation Genetic Testing (PGT)
Pre-implantation genetic testing is a critical component of assisted reproductive technology, helping clinicians assess the genetic health of embryos before implantation. IVI RMA research emphasizes the importance of standardized protocols for PGT, highlighting how consistency can improve the reliability of results and provide patients with clearer guidance about their reproductive options.
4. Reproductive Potential of Embryos with Segmental Aneuploidy
Some embryos may exhibit small chromosomal anomalies, such as deletions or duplications, known as segmental aneuploidy. Research from IVI RMA demonstrates that these embryos can still lead to successful live births, challenging conventional assumptions and expanding the possibilities for patients undergoing IVF. These findings have significant implications for clinical decision-making and counseling in reproductive medicine.
5. Recurrent Pregnancy Loss in Frozen Embryo Transfers
Another focus of IVI RMA research is the prevalence and impact of recurrent pregnancy loss in women undergoing frozen embryo transfers. Studies indicate that such losses are relatively uncommon and are unlikely to adversely affect the success of future transfers. This evidence provides reassurance to patients and helps clinicians optimize treatment protocols for those experiencing previous pregnancy challenges.
Christine Whitehead, MS, BSN, RN, Director of Research Operations at IVI RMA North America, emphasized the organization’s longstanding commitment to advancing reproductive science: “For nearly three decades, IVI RMA has been at the forefront of evidence-based fertility research, contributing thousands of papers and abstracts to the field. Our global research centers are integral to our clinical care, and our dedicated researchers work tirelessly to push the boundaries of reproductive medicine forward.”
The breadth of IVI RMA’s contributions at ASRM 2025 highlights the organization’s dual focus on scientific rigor and patient-centered care. By integrating research insights into clinical practice, IVI RMA ensures that the latest discoveries translate into tangible improvements in patient outcomes. From evaluating novel diagnostic tools to exploring innovative treatment protocols, IVI RMA’s research portfolio underscores the organization’s leadership in shaping the future of reproductive medicine.
The ASRM Annual Scientific Congress & Expo provides an unparalleled platform for disseminating these advancements, facilitating knowledge exchange among reproductive medicine professionals worldwide. Attendees at the 2025 congress will have the opportunity to engage directly with IVI RMA researchers, gaining insight into the latest developments in fertility treatment, reproductive biology, and emerging technologies such as AI-assisted embryo assessment.
In addition to presenting research findings, IVI RMA will demonstrate its ongoing commitment to innovation through poster sessions and interactive presentations that encourage dialogue and collaboration. These sessions cover both clinical and laboratory research, providing a comprehensive view of the organization’s multifaceted approach to reproductive medicine.
In conclusion, IVI RMA North America’s participation in ASRM 2025 underscores the organization’s leadership in reproductive medicine and its commitment to advancing science, technology, and patient care on a global scale. Through extensive presentations, cutting-edge research, and a focus on evidence-based clinical practice, IVI RMA continues to provide clinicians and patients with the tools, knowledge, and insights necessary to achieve optimal fertility outcomes. The organization’s work at the congress promises to contribute meaningfully to the global dialogue on reproductive health, pushing the boundaries of what is possible in family building and fertility care.
